TY - JOUR
T1 - Regression of left ventricular hypertrophy
T2 - Are there preferred drugs?
AU - Diamond, Joseph A.
AU - Phillips, Robert A.
PY - 2003/1/1
Y1 - 2003/1/1
N2 - The presence of left ventricular hypertrophy (LVH) confers markedly increased risk of cardiovascular morbidity and mortality in patients with hypertension. Regression of left ventricular (LV) mass with antihypertensive therapy is associated with reduction in cardiovascular events. In studies based on monotherapy, among the classes of antihypertensive drugs that have been adequately tested, diuretics and angiotensin-converting enzyme inhibitors appear to be the most effective agents for reducing LV mass. New avenues of research, based on combination antihypertensive therapy and on a more sophisticated understanding of the molecular mechanisms of LVH, may yield new pharmacologic approaches to regressing LV mass.
AB - The presence of left ventricular hypertrophy (LVH) confers markedly increased risk of cardiovascular morbidity and mortality in patients with hypertension. Regression of left ventricular (LV) mass with antihypertensive therapy is associated with reduction in cardiovascular events. In studies based on monotherapy, among the classes of antihypertensive drugs that have been adequately tested, diuretics and angiotensin-converting enzyme inhibitors appear to be the most effective agents for reducing LV mass. New avenues of research, based on combination antihypertensive therapy and on a more sophisticated understanding of the molecular mechanisms of LVH, may yield new pharmacologic approaches to regressing LV mass.
UR - http://www.scopus.com/inward/record.url?scp=0642343043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0642343043&partnerID=8YFLogxK
U2 - 10.1007/s11906-003-0081-2
DO - 10.1007/s11906-003-0081-2
M3 - Review article
C2 - 12948428
AN - SCOPUS:0642343043
SN - 1522-6417
VL - 5
SP - 368
EP - 371
JO - Current Hypertension Reports
JF - Current Hypertension Reports
IS - 5
ER -